Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.

Moderna Cuts Sales Forecast on UK Revenue Delay, Shares Fall

Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.

Moderna also lost less than Wall Street analysts were expecting for the second quarter and posted revenue that topped estimates.

Moderna’s Loss Narrows After Cost-Cutting Efforts Take Hold

Moderna Inc.’s second-quarter loss was narrower than Wall Street expected as the struggling biotech company cuts costs to offset waning sales of its Covid shot.

Moderna's Revenue Outlook Decline - PressReach

Moderna Inc. (NASDAQ:MRNA), a leader in mRNA technology, recently announced a reduction in its revenue forecast due to delays in vaccine deliveries to the United Kingdom. The company, known for its COVID-19 vaccine, has been facing logistical challenges that have affected its financial projections. As a result, Moderna’s stock experienced a notable drop in response to the revised outlook. The pharmaceutical giant initially projected significant …

Moderna Reports 41% Revenue Decline in Q2 2025 and Plans $1.5 Billion Cost-Cutting Initiative

Moderna announced a 41% decline in revenue for the seco […]